Gastritis is an inflammation of the gastric mucosa. In this study, we investigated the efficacy of a medical device, Esoxx®, basedon hyaluronic acid and chondroitin sulfate on gastritis-related upper abdominal pain/discomfort and endoscopic features. Fiftypatients, affected by gastritis, were randomised to receive the medical device or placebo. The primary endpoint was the medicaldevice efficacy on upper abdominal pain/discomfort associated with gastritis and measured byVisual Analogue Scale (VAS). Thesecondary endpoints were the efficacy of the medical device on gastritis-related mucosal erosions, blood oozing, and hyperemia(redness)/edema, as assessed by endoscopy, and the patients’ rating of their compliance with the treatments. A significantreduction in VAS pain was observed in the treatment group after a 5-week treatment, if compared with placebo (p < 0.001). Insummary, administration of a medical device, based on hyaluronic acid and chondroitin sulfate, improves gastritis-related upperabdominal pain/discomfort and decreases mucosal erosions, blood oozing, and hyperemia (redness)/edema at 5-week follow-upin patients affected by gastritis.